The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers-Reference-Cited by-同舟云学术

The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers

Published:2014-02-06 Issue:3 Volume:3 Page:202-206
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:

Author:

Vourvahis Manoli¹,Fang Juanzhi²,Choo Heng Wee³,Heera Jayvant²

Affiliation:

1. Pfizer Global Research and Development; New York NY USA

2. Pfizer Global Research and Development; Groton CT USA

3. Pfizer Clinical Research Unit; Singapore Singapore

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference29 articles.

1. Food and Drug Administration, Selzentry: highlights of prescribing information 2007 http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022128lbl.pdf

2. European Medicines Agency. Celsentri (maraviroc), European Public Assessment Report 2011 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000811/human_med_000689.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124

3. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects;Abel;Br J Clin Pharmacol.,2008

4. In vitro and in vivo glucuronidation of midazolam in humans;Hyland;Br J Clin Pharmacol.,2009

5. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T > C polymorphism;Siccardi;Pharmacogenet Genomics.,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds;Frontiers in Oncology;2022-08-29

2. Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices;Pharmaceuticals;2022-02-18